Pfizer to Advance Industry Leadership Through the Best People, Products And Pipeline, Steere Tells Shareholders 2001 Planned R&D Budget of $5 Billion Leads Industry



Four New Drugs Currently Undergoing Regulatory Review;

Pipeline Includes 7 Late-Stage and 22 Mid-Stage Candidates



    GROTON, Conn., April 26 /PRNewswire/ -- Pfizer Inc is positioned for
 continuing growth that will sustain its industry leadership, William C.
 Steere, Jr., chairman, said today at the company's 2001 Annual Meeting of
 Shareholders.
     Speaking at the Pfizer Global Research and Development Groton campus,
 Mr. Steere said, "Pfizer is advancing in every area.  Our fundamentals are
 strong.  Our pipeline is broad and deep, and our field forces are second to
 none.  Pfizer success depends heavily on the insights, skill and ingenuity of
 our people.  And because of them, I'm extremely confident about our company's
 future."
     Mr. Steere, who has been chairman of Pfizer since 1991, is retiring from
 the post effective May 1.  Hank McKinnell, Ph.D.,  Pfizer's president and
 chief executive officer, and the incoming chairman, said, "Pfizer capped a
 remarkable decade of growth and achievement in the year 2000.  It is fitting
 that, today, we honor the architect of that success, our chairman, Bill
 Steere.  Bill joined Pfizer in 1959, coming to a company with $250 million in
 worldwide sales.  Today, Pfizer is the world's most recognized and respected
 name in pharmaceuticals."
     Dr. McKinnell said that in the first quarter of 2001, Pfizer had net
 income growth of 34 percent and diluted earnings per share growth of
 32 percent, with both results excluding certain significant items and merger
 related costs.  "We fully expect to generate at least 25 percent average
 annual EPS growth for the period 2000 through 2002."
     Dr. McKinnell highlighted Pfizer's industry leading portfolio of
 pharmaceutical products, noting that it included seven of the world's top
 30 selling drugs.  Eight Pfizer products, either discovered or co-marketed by
 Pfizer, are generating annual revenues of more than $1 billion each.  Pfizer
 sees "great room for continued growth for Lipitor", which exceeded $5 billion
 in 2000 sales.
     John F. Niblack, Ph.D., vice chairman of Pfizer Inc, and president of
 Pfizer Global Research and Development said Pfizer has the facilities and
 technologies for the most sophisticated research approaches, including those
 based on new understanding of the human genome.
     Dr. Niblack noted that an important new Pfizer product, Geodon, was
 launched in the U.S. last month.  Discovered and developed by Pfizer
 scientists, Geodon treats all the symptoms of schizophrenic psychoses and has
 a very favorable side-effect profile that causes little to no weight gain and
 has a favorable effect on blood lipid levels.
     Pfizer expects to follow Geodon with four new drugs that are all currently
 under regulatory review in the U.S. and/or abroad: Relpax for migraine; Vfend,
 an antifungal; Spiriva, co-promoted with Boehringer Ingelheim, for pulmonary
 disease and Valdecoxib, co-promoted with Pharmacia, for pain and inflammation.
     "Coming next," he said, "are seven major late-stage development
 candidates, spanning major disease areas from diabetes to atherosclerosis."
 He detailed progress on three programs scheduled to conclude and be filed for
 regulatory review this year and next: Exubera or inhaled insulin, co-promoted
 with Aventis Pharma; pregabalin for treatment of neuropathic pain and
 epilepsy; and darifenacin for overactive bladder.  The other late-stage
 candidates are lasofoxifene for treatment and prevention of osteoporosis;
 capravirine for HIV; pagaclone for panic and anxiety disorders; and avasimibe
 for atherosclerosis.
     "These important new drug candidates should contribute strongly to
 maintaining the momentum of Pfizer's pharmaceutical business for years to
 come."
     Dr. Niblack also discussed a new agent from the mid-stage pipeline for
 smoking cessation that relieves both cravings and withdrawal symptoms and
 blocks the reinforcing effect of smoking.  "CP-526,555 clearly works.  Studies
 are in progress to measure safety and efficacy in larger patient populations,
 and for longer periods of follow-up.  If the results from these studies are as
 good as what we have seen to date, CP-526,555 will move rapidly forward into
 advanced development."  He added that Pfizer has 22 mid-stage candidates which
 span a spectrum of therapeutic areas as diverse as stroke, pulmonary
 hypertension, frailty and cancer.
     Pfizer's R&D pipeline, includes approximately 150 research programs in
 19 therapeutic areas.  "Many competitors would be daunted by the challenge of
 pursuing so many opportunities at once," Dr. Niblack said.  "We are not."
     In discussing Pfizer's Animal Health business, Dr. McKinnell noted,
 " ... that Animal Health has a full pipeline of more than 40 projects in
 development.  This year, we expect approvals of several important new claims
 and line extensions for our key products.  In addition, two new long-lasting
 antimicrobials for companion animals and livestock have entered full
 development."
     Pfizer's Consumer Healthcare Division Shaving Products, Adams Division and
 Tetra all plan line extensions or launches of new products in 2001,
 Dr. McKinnell said.
     Dr. McKinnell also discussed Pfizer's continuing support and development
 of innovative philanthropic partnership programs to improve access to Pfizer
 medicines including:
 
      --   Diflucan Partnership program in South Africa that is providing
           $50 million worth of the antifungal Diflucan free of charge to all
           AIDS patients in that country who do not have access to medications.
 
      --   Sharing the Care program in the U.S. which since 1993 has provided
           more than 1 million uninsured patients with Pfizer pharmaceuticals
           free of charge.
 
      --   International Trachoma Initiative (ITI) that is active in seven
           countries in Asia/Africa and committed to eliminating blinding
           trachoma by 2020.  Pfizer is contributing more than $60 million in
           medicines and funding to ITI.
 
     Dr. McKinnell said, "As important as these programs are, the best way for
 Pfizer to help address these global health issues is by discovering and
 developing breakthrough drugs.  We are striving to be the company that does
 more good for more people than any other company on the planet."
 
     Pfizer Inc discovers, develops, manufactures and markets leading
 prescription medicines, for humans and animals, and many of the world's best
 known consumer products.  Pfizer had global revenues of $29.6 billion in 2000.
 Pfizer plans to make a research and development investment of about $5 billion
 in 2001.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X59661554
 
 

SOURCE Pfizer Inc
RELATED LINKS
http://www.pfizer.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.